Familial myeloma

New England Journal of Medicine

Volumn 359, Issue 2, 2008, Pages 152-157

  Lynch, Henry T ^a   Ferrara, Kelly ^a   Barlogie, Bart ^d   Coleman, Elizabeth A ^d   Lynch, Jane F ^a   Weisenburger, Dennis ^b   Sanger, Warren ^b   Watson, Patrice ^a   Nipper, Henry ^c   Witt, Vinetta ^e   Thomé, Stephan ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

^c CREIGHTON UNIVERSITY   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e NEWBERRY COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL DISEASE; FEMALE; GAMMOPATHY; HUMAN; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGENY; PROSTATE CANCER; STEM CELL;

EID: 46949099848     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0708704     Document Type: Article

References (21)

1. Malpas JS, Bergsagel DE, Kyle R, Anderson K. Multiple myeloma: biology and management. Oxford, England: Oxford University Press, 1998.
2. Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother 2002;56:223-34.
3. Alexander DD, Mink PJ, Adami H-O, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007; 120:Suppl 12:40-61.
4. Gerkes EH, de Jong MM, Sijmons RH, Vellenga E. Familial multiple myeloma: report on two families and discussion of screening options. Hered Cancer Clin Pract 2007;5:72-8.
5. Keren DF. Monoclonal gammopathies. In: McClatchey KD, ed. Clinical laboratory medicine. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2002:1448-57.
6. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006;134:573-89.
7. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006;107:904-6.
8. Lynch HT, Watson P, Tarantolo S, et al. Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 2005;23: 685-93.
9. Lynch HT. Family Information Service and hereditary cancer. Cancer 2001;91: 625-8.
10. Jeppson JO, Laurell CB, Franzén B. Agarose gel electrophoresis. Clin Chem 1979;25:629-38.
11. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-80.
12. Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 2007;82: 1468-73.
13. Breslow NE, Day NF. Statistical methods in cancer research. Vol. 2. The design and analysis of cohort studies. Lyon, Fr ance: International Agency for Research on Cancer, 1987. (IARC scientific publications no. 82.)
14. Lynch HT, Sanger WG, Pirruccello S, Quinn-Laquer B, Weisenburger DD. Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst 2001;93:1479-83.
15. Ögmundsdóttir HM, Haraldsdóttir V, Jóhannesson GM, et al. Familiality of benign and malignant paraproteinemias: a population-based cancer-registry study of mult iple myeloma fa milies. Haematologica 2005;90:66-71.
16. Eriksson M, Hallberg B. Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study. Cancer Causes Control 1992;3:63-7.
17. Zighelboim I, Babb S, Gao F, Powell MA, Mutch DG, Goodfellow PJ. Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility. Gynecol Oncol 2007;105:390-4.
18. Brown LM, Linet MS, Greenberg RS, et al. Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer 1999;85:2385-90.
19. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
20. Dilworth D, Liu L, Stewart K, Berenson JR, Lassam N, Hogg D. Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood 2000; 95:1869-71.
21. Lynch HT, Brand RE, Hogg D, et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical multiple mole melanoma-pancreatic carcinoma syndrome. Cancer 2002;94:84-96.